Effect of valproic acid on seizure control and on survival in patients with glioblastoma multiforme
Top Cited Papers
Open Access
- 16 May 2013
- journal article
- research article
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 15 (7), 961-967
- https://doi.org/10.1093/neuonc/not057
Abstract
To examine the efficacy of valproic acid (VPA) given either with or without levetiracetam (LEV) on seizure control and on survival in patients with glioblastoma multiforme (GBM) treated with chemoradiation. A retrospective analysis was performed on 291 patients with GBM. The efficacies of VPA and LEV alone and as polytherapy were analyzed in 181 (62%) patients with seizures with a minimum follow-up of 6 months. Cox-regression survival analysis was performed on 165 patients receiving chemoradiation with temozolomide of whom 108 receiving this in combination with VPA for at least 3 months. Monotherapy with either VPA or LEV was instituted in 137/143 (95.8%) and in 59/86 (68.6%) on VPA/LEV polytherapy as the next regimen. Initial freedom from seizure was achieved in 41/100 (41%) on VPA, in 16/37 (43.3%) on LEV, and in 89/116 (76.7%) on subsequent VPA/LEV polytherapy. At the end of follow-up, seizure freedom was achieved in 77.8% (28/36) on VPA alone, in 25/36 (69.5%) on LEV alone, and in 38/63 (60.3%) on VPA/LEV polytherapy with ongoing seizures on monotherapy. Patients using VPA in combination with temozolomide showed a longer median survival of 69 weeks (95% confidence interval [CI]: 61.7–67.3) compared with 61 weeks (95% CI: 52.5–69.5) in the group without VPA (hazard ratio, 0.63; 95% CI: 0.43–0.92; P = .016), adjusting for age, extent of resection, and O6-DNA methylguanine-methyltransferase promoter methylation status. Polytherapy with VPA and LEV more strongly contributes to seizure control than does either as monotherapy. Use of VPA together with chemoradiation with temozolomide results in a 2-months’ longer survival of patients with GBM.This publication has 32 references indexed in Scilit:
- Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastomaNeurology, 2011
- Combining antiepileptic drugs—Rational polytherapy?Seizure, 2011
- Efficacy and Safety of Levetiracetam in Patients With GliomaArchives of Neurology, 2010
- Efficacy of anti-epileptic drugs in patients with gliomas and seizuresZeitschrift für Neurologie, 2009
- Safety and feasibility of switching from phenytoin to levetiracetam monotherapy for glioma-related seizure control following craniotomy: a randomized phase II pilot studyJournal of Neuro-Oncology, 2009
- Review: Is levetiracetam different from other antiepileptic drugs? Levetiracetam and its cellular mechanism of action in epilepsy revisitedTherapeutic Advances in Neurological Disorders, 2008
- SV2A protein is a broad-spectrum anticonvulsant target: Functional correlation between protein binding and seizure protection in models of both partial and generalized epilepsyNeuropharmacology, 2008
- SURGERY FOR TEMPORAL MEDIOBASAL TUMORSNeurosurgery, 2007
- Levetiracetam: preliminary experience in patients with primary brain tumoursSeizure, 2003
- Practice parameter: Anticonvulsant prophylaxis in patients with newly diagnosed brain tumors [RETIRED]Neurology, 2000